Ajanta Pharma Limited
Tata AIA Life Insurance raised its stake in Ajanta Pharma from 1.90% to 1.91%, purchasing 13,490 shares.
A manufacturer of specialty pharmaceutical finished dosages, this company develops and markets formulations across therapeutic categories including ophthalmology, gastroenterology, and dermatology for domestic and international markets. With vertically integrated operations spanning development, manufacturing, and marketing, the company has established a significant presence in India's pharmaceutical sector through its robust distribution network and focus on quality production.
Joint venture between Tata Sons and AIA Group. AUM crossed Rs 1.3 lakh crore in May 2025, growing 27% YoY, making it one of the fastest-growing equity-oriented insurers in India. CIO Harshad Patil has run the investment book since 2014. Flagship Multi Cap Fund delivered 31.4% CAGR over 5 years, among the strongest performance in the ULIP universe.